BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17613529)

  • 1. Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F.
    Komissarov AA; Zhou A; Declerck PJ
    J Biol Chem; 2007 Sep; 282(36):26306-15. PubMed ID: 17613529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.
    Olson ST; Swanson R; Day D; Verhamme I; Kvassman J; Shore JD
    Biochemistry; 2001 Oct; 40(39):11742-56. PubMed ID: 11570875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
    Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
    J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
    Kvassman JO; Verhamme I; Shore JD
    Biochemistry; 1998 Nov; 37(44):15491-502. PubMed ID: 9799512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural determinants in the stability of the serpin/proteinase complex.
    De Taeye B; Verbeke K; Compernolle G; Biesemans W; Gils A; Declerck PJ
    Biochem Biophys Res Commun; 2003 Aug; 307(3):529-34. PubMed ID: 12893254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition.
    Ibarra CA; Blouse GE; Christian TD; Shore JD
    J Biol Chem; 2004 Jan; 279(5):3643-50. PubMed ID: 14594804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies.
    Bijnens AP; Gils A; Knockaert I; Stassen JM; Declerck PJ
    J Biol Chem; 2000 Mar; 275(9):6375-80. PubMed ID: 10692438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies.
    Komissarov AA; Declerck PJ; Shore JD
    J Biol Chem; 2002 Nov; 277(46):43858-65. PubMed ID: 12223472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protonation state of a single histidine residue contributes significantly to the kinetics of the reaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator.
    Komissarov AA; Declerck PJ; Shore JD
    J Biol Chem; 2004 May; 279(22):23007-13. PubMed ID: 15033993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
    Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.
    Wind T; Jensen MA; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(4):1095-106. PubMed ID: 11179976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.
    Li SH; Gorlatova NV; Lawrence DA; Schwartz BS
    J Biol Chem; 2008 Jun; 283(26):18147-57. PubMed ID: 18436534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand.
    Jensen JK; Wind T; Andreasen PA
    FEBS Lett; 2002 Jun; 521(1-3):91-4. PubMed ID: 12067733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
    Egelund R; Petersen TE; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents.
    Bødker JS; Wind T; Jensen JK; Hansen M; Pedersen KE; Andreasen PA
    Eur J Biochem; 2003 Apr; 270(8):1672-9. PubMed ID: 12694180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of helix F in plasminogen activator inhibitor-1.
    Vleugels N; Gils A; Bijnens AP; Knockaert I; Declerck PJ
    Biochim Biophys Acta; 2000 Jan; 1476(1):20-6. PubMed ID: 10606763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
    Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms.
    Hansen M; Busse MN; Andreasen PA
    Eur J Biochem; 2001 Dec; 268(23):6274-83. PubMed ID: 11733024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.